Xing-Fei Yu1, Wei-Liang Feng, Lu-Lu Miao, Bo Chen, Hong-Jian Yang. 1. Department of Breast Tumor Surgery, Zhejiang Cancer Hospital, 38# Guangji Lu, Banshan Qiao, Hangzhou, Zhejiang Province 310022, PR China. Electronic address: yxfecho@yahoo.com.cn.
Abstract
BACKGROUND: Male breast cancer (MBC) is rare. Molecular subtype has been utilized widely in female breast cancer. But the relationship between subtype and prognosis in MBC patients is still unknown. We aim to study the impact of molecular subtype on the prognosis of MBC. METHODS: We identified MBC cases from 1990 to 2011 retrospectively; molecular subtype was assigned by immunohistochemistry. We compared overall survival in different subtypes by Kaplan-Meier method and COX proportional hazard regression model. RESULTS: 68 patients with MBC were included in analysis with 115 months of a median follow-up time. Comparing to non-luminal A (subtypes of Luminal B, HER2 over-express and Basal-like) group, patients with luminal A had a lower recurrent rate and better overall survival (10-year survival rate was 78.0% vs 67.0%, mean survival time 197.46 ± 12.22 months vs 146.51 ± 16.88 months, p < 0.05). CONCLUSION: Molecular subtype may have prognosis-predicting value for MBC.
BACKGROUND:Male breast cancer (MBC) is rare. Molecular subtype has been utilized widely in female breast cancer. But the relationship between subtype and prognosis in MBCpatients is still unknown. We aim to study the impact of molecular subtype on the prognosis of MBC. METHODS: We identified MBC cases from 1990 to 2011 retrospectively; molecular subtype was assigned by immunohistochemistry. We compared overall survival in different subtypes by Kaplan-Meier method and COX proportional hazard regression model. RESULTS: 68 patients with MBC were included in analysis with 115 months of a median follow-up time. Comparing to non-luminal A (subtypes of Luminal B, HER2 over-express and Basal-like) group, patients with luminal A had a lower recurrent rate and better overall survival (10-year survival rate was 78.0% vs 67.0%, mean survival time 197.46 ± 12.22 months vs 146.51 ± 16.88 months, p < 0.05). CONCLUSION: Molecular subtype may have prognosis-predicting value for MBC.
Authors: Julieta Leone; Rachel A Freedman; Nancy U Lin; Sara M Tolaney; Carlos T Vallejo; Bernardo A Leone; Eric P Winer; José Pablo Leone Journal: Breast Cancer Res Treat Date: 2021-03-26 Impact factor: 4.872
Authors: Alfonso Sánchez-Muñoz; Luis Vicioso; Angela Santonja; Martina Álvarez; Yéssica Plata-Fernández; José Miramón; Irene Zarcos; César L Ramírez-Tortosa; Julio Montes-Torres; José M Jerez; Vanessa de Luque; Casilda Llácer; Cristina E Fernández-De Sousa; Lidia Pérez-Villa; Emilio Alba Journal: Mod Pathol Date: 2017-10-06 Impact factor: 7.842
Authors: Marie Colombe Agahozo; Mieke A M Timmermans; Hein F B M Sleddens; Renée Foekens; Anita M A C Trapman-Jansen; Carolien P Schröder; Elise van Leeuwen-Stok; John W M Martens; Winand N M Dinjens; Carolien H M van Deurzen Journal: Cancers (Basel) Date: 2020-03-09 Impact factor: 6.639